Phaseline

Companies › Larimar Therapeutics

Larimar Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 3; Neurology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nomlabofusp
Recombinant human frataxin fusion protein
FXNPhase 3Friedreich AtaxiaJul 2029
CTI-1601
Recombinant fusion protein delivering human frataxin
FXNPhase 2Friedreich AtaxiaJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06447025CTI-1601Phase 2Friedreich AtaxiaNeurologyJan 2027
NCT07778836NomlabofuspPhase 3Friedreich AtaxiaNeurologyJul 2029

From the company's SEC filings

Cash and short-term investments of $156m on 2026-06-30; operating cash outflow about $180m a year; runway about 10 months at that burn, to May 2027; 1 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

FXN (2)

Companies with the same targets

Lexeo Therapeutics Solid Biosciences

Companies built like this

IGC Pharma Biohaven Pharmaceuticals Annovis Bio Immunic Satellos Bioscience

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.